- Home
- PPBI vs APGE Comparison
PPBI vs APGE Comparison
Compare PPBI & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBI
- APGE
- Stock Information
- Founded
- PPBI 1983
- APGE 2022
- Country
- PPBI United States
- APGE United States
- Employees
- PPBI N/A
- APGE N/A
- Industry
- PPBI Major Banks
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PPBI Finance
- APGE Health Care
- Exchange
- PPBI Nasdaq
- APGE Nasdaq
- Market Cap
- PPBI 2.2B
- APGE 2.6B
- IPO Year
- PPBI 1997
- APGE 2023
- Fundamental
- Price
- PPBI $22.57
- APGE $40.82
- Analyst Decision
- PPBI Buy
- APGE Strong Buy
- Analyst Count
- PPBI 4
- APGE 4
- Target Price
- PPBI $27.25
- APGE $97.50
- AVG Volume (30 Days)
- PPBI 1.2M
- APGE 1.3M
- Earning Date
- PPBI 07-24-2025
- APGE 08-11-2025
- Dividend Yield
- PPBI 5.96%
- APGE N/A
- EPS Growth
- PPBI N/A
- APGE N/A
- EPS
- PPBI 1.43
- APGE N/A
- Revenue
- PPBI $584,278,000.00
- APGE N/A
- Revenue This Year
- PPBI N/A
- APGE N/A
- Revenue Next Year
- PPBI $6.74
- APGE $743.14
- P/E Ratio
- PPBI $15.55
- APGE N/A
- Revenue Growth
- PPBI 48.04
- APGE N/A
- 52 Week Low
- PPBI $18.06
- APGE $26.20
- 52 Week High
- PPBI $30.28
- APGE $63.50
- Technical
- Relative Strength Index (RSI)
- PPBI 56.38
- APGE 52.23
- Support Level
- PPBI $21.15
- APGE $37.05
- Resistance Level
- PPBI $22.41
- APGE $42.29
- Average True Range (ATR)
- PPBI 0.60
- APGE 2.01
- MACD
- PPBI -0.06
- APGE 0.18
- Stochastic Oscillator
- PPBI 70.65
- APGE 77.66
About PPBI Pacific Premier Bancorp Inc
Pacific Premier Bancorp Inc through its subsidiaries, provides banking products and services. It offers cash management, electronic banking services, credit facilities, and retirement accounts, among others.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.